TickerFacts.

Company research / CCEL

Cryo Cell International Inc (CCEL)

Build a valuation ↗↓ Download CSV

SEC name CRYO CELL INTERNATIONAL INC · CIK 0000862692 · NYSE · Services-Misc Health & Allied Services, NEC

  • Sector Services
  • Incorporated DE
  • Fiscal year ends Nov 30

For the year ended 2025-11-30, Cryo Cell International Inc reported revenue of $31.57M. Revenue fell 1.3% from the prior annual period. Over the twelve months to 2026-08-31, revenue was $31.13M.

Key ratios (year ended 2025-11-30)

76.6%
Gross margin (computed)
1.5%
Operating margin
-7.7%
Net margin
-1.3%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form DEF 14A (proxy statement) · 2026-10-13

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-08-31 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-08-31		2025-11-302024-11-302023-11-302022-11-302021-11-302020-11-302019-11-302018-11-302017-11-302016-11-30
Revenue$31.13M$31.57M$31.99M$31.34M$30.34M$28.88M$31.15M$31.82M$29.22M$25.38M$23.13M
Cost of Revenue$6.68M$7.38M$7.95M$8.39M$8.79M$8.99M$9.66M$10.04M$8.54M$6.72Mn/a
Gross Profit (computed)$24.45M$24.19M$24.04M$22.95M$21.54M$19.90M$21.49M$21.78M$20.68M$18.66Mn/a
R&D Expense$303.9K$376.3K$1.24M$1.17M$384.8K$49.9K$23.9K$30.1K$91.8K$41.2K$53.1K
Operating Income$189.4K$482.4K$3.48M-$12.30M$4.02M$4.02M$7.66M$5.06M$5.19M$5.01M$433.6K
Depreciation & Amortization$736.5K$751.5K$483.5K$1.12M$1.12M$834.8K$166.4K$206.2K$180.3K$131.6K$154.7K
EBITDA$925.9K$1.23M$3.96M-$11.18M$5.14M$4.85M$7.83M$5.27M$5.37M$5.14M$588.3K
Net Income-$1.95M-$2.43M$402.1K-$9.52M$2.77M$2.08M$3.62M$2.29M-$854.8K$2.32M-$1.32M
EPS (Diluted)n/a-$0.30$0.05-$1.14$0.33$0.25$0.45$0.27-$0.11$0.30-$0.16
Total Assets$62.30M$61.73M$64.68M$61.22M$64.89M$60.66M$46.20M$42.89M$42.39M$23.91M$19.54M
Total Liabilities$78.70M$80.33M$77.89M$72.25M$66.41M$56.48M$48.87M$49.84M$51.30M$36.41M$34.95M
Long-Term Debt$8.24M$8.35M$8.48M$8.60M$8.73M$1.90M$5.94M$8.96M$12.94M$7.30M$9.82M
Shareholders' Equity-$16.39M-$18.61M-$13.22M-$11.03M-$1.52M$4.18M-$2.67M-$6.95M-$8.91M-$12.50M-$15.41M
Cash & Equivalents$1.43M$319.0K$561.0K$406.1K$1.70M$8.26M$10.36M$6.54M$6.04M$6.28M$3.50M
Operating Cash Flow$4.92M$5.48M$6.01M$8.92M$8.57M$7.93M$8.47M$6.29M$5.33M$5.72M$4.99M
Capital Expenditures$268.9K$230.5K$2.40M$6.84M$12.17M$1.83M$100.0K$662.3K$446.2K$98.3K$343.0K
Free Cash Flow$4.65M$5.25M$3.61M$2.08M-$3.60M$6.09M$8.37M$5.63M$4.89M$5.62M$4.64M
Share Repurchases$0$169.5K$1.42M$799.0K$1.82M$249.4Kn/a$992.2Kn/a$446.6K$10.81M
Dividends Paid$0$3.23M$2.02M$0$7.67M$0n/an/an/an/an/a
Shares Outstanding8.06M8.06M8.08M8.29M8.50M8.55M7.55M7.51M7.80M7.10M6.79M
Dividends Per Sharen/an/a$0.25n/a$0.90n/an/an/an/an/an/a
Weighted Average Diluted Sharesn/a8.07M8.21M8.34M8.48M8.36M8.14M8.41M7.46M7.65M8.11M
EPS (Basic)n/a-$0.30$0.05-$1.14$0.33$0.26$0.48$0.29-$0.11$0.33-$0.16

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView